No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
173 |
4. Check minimum number of eventsNone |
173 |
5. Include endpoints |
195 |
6. Filter based on genotype QC (FinnGen only) |
174 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E70-E90
- Name in latin
- Aliae perturbationes metabolismi acidorum aminoicorum
Similar endpoints
↥List of similar endpoints to
Other disorders of amino-acid metabolism
based on the number of shared cases.
Similar with more cases:
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1745 | 846 | 887 |
| Only index persons | 1331 | 659 | 672 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 52.90 | 55.02 | 50.64 |
| Only index persons | 53.93 | 55.81 | 52.09 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 174 | 88 | 86 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.04 |
| Median age at first event (years) | 53.94 | 48.33 | 59.68 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 179
- Matched controls
- 1790
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E72.0
ICD-10 Finland
Disorders of amino-acid transport
+∞
57.4
52
*
E72.2
ICD-10 Finland
Disorders of urea cycle metabolism
+∞
33.4
31
*
E72.8
ICD-10 Finland
Other specified disorders of amino-acid metabolism
+∞
26.7
25
*
E72.5
ICD-10 Finland
Disorders of glycine metabolism
+∞
24.5
23
*
503
Kela drug reimbursment
Inborn metabolic disorders
+∞
24.5
23
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.4
22.3
55
135
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
4.9
17.4
46
118
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.3
16.8
56
172
103
Kela drug reimbursment
Diabetes, insulin-treated
3.8
16.0
72
272
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.3
15.3
28
51
A10AB05
ATC
insulin aspart; parenteral
5.5
15.2
33
71
E72.4
ICD-10 Finland
Disorders of ornithine metabolism
+∞
14.8
14
*
E72.9
ICD-10 Finland
Disorder of amino-acid metabolism, unspecified
+∞
14.8
14
*
C10AA01
ATC
simvastatin; oral
3.4
14.6
92
426
124
Kela drug reimbursment
Inborn metabolic disorders
+∞
13.7
13
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.7
13.6
54
185
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.5
13.1
59
219
A10AE04
ATC
insulin glargine; parenteral
4.6
12.7
34
87
E72.3
ICD-10 Finland
Disorders of lysine and hydroxylysine metabolism
+∞
12.6
12
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
6.1
12.5
23
42
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.4
12.3
60
233
A10BA02
ATC
metformin; oral
3.2
11.9
67
283
A10AC01
ATC
insulin (human); parenteral
4.6
11.8
31
78
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
10.0
11.7
23
26
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.2
10.6
23
49
L28
ICPC
Limited function/disability (L)
3.2
10.3
50
192
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.1
10.2
31
87
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.2
10.2
49
187
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
42.6
10.1
12
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.6
9.8
38
126
A10AE05
ATC
insulin detemir; parenteral
5.3
9.8
21
44
N17.9
ICD-10 Finland
Acute renal failure, unspecified
8.9
9.6
20
25
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.2
9.6
21
45
C03CA01
ATC
furosemide; systemic
2.7
9.5
74
366
E72.1
ICD-10 Finland
Disorders of sulfur-bearing amino-acid metabolism
+∞
9.5
9
*
ZXD05
NOMESCO Finland
Urgent procedure
2.7
9.1
70
343
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
3.9
8.9
29
85
D64.9
ICD-10 Finland
Anaemia, unspecified
3.6
8.9
33
106
N05CD07
ATC
temazepam; oral
3.5
8.8
34
112
C01DA14
ATC
isosorbide mononitrate; oral
3.4
8.8
37
129
I25.1
ICD-10 Finland
Atherosclerotic heart disease
3.0
8.8
49
202
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
8.8
101
600
TK800
NOMESCO Finland
Hemodialysis
12.5
8.7
15
13
T90
ICPC
Diabetes non-insulin dependent
2.9
8.7
53
229
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
29.1
8.6
11
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
8.3
63
305
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
8.1
39
147
M04AA01
ATC
allopurinol; systemic
3.2
8.0
35
125
SPAT1229
SPAT
Assessment of need for aid
4.3
8.0
22
57
A11CC03
ATC
alfacalcidol; systemic
12.6
7.7
13
11
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.6
7.7
13
11
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.3
7.6
31
106
C01DA02
ATC
glyceryl trinitrate; oral, oral aerosol, sublingual, transdermal
2.8
7.5
44
185
J01FF01
ATC
clindamycin; systemic
2.5
7.4
60
298
A07AA11
ATC
rifaximin; oral
+∞
7.3
7
*
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
16.6
7.3
11
7
D01AE15
ATC
terbinafine; topical
4.0
7.3
22
61
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
21.0
7.2
10
5
E87.6
ICD-10 Finland
Hypokalaemia
21.0
7.2
10
5
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.9
7.2
40
164
AN1
HP
Coronary angiography
3.7
7.1
24
72
205
Kela drug reimbursment
Chronic hypertension
2.5
7.1
55
266
AA1AD
NOMESCO Finland
CT of head and brain
2.5
7.0
59
297
213
Kela drug reimbursment
Fat metabolism disorder associated with chronic coronary artery disease
4.0
7.0
21
58
E11.00
ICD-10 Finland
Non-insulin dependent diabetes diabetic hypoglycaemic coma
7.7
6.9
15
21
Z49.1
ICD-10 Finland
Extracorporeal dialysis
17.5
6.8
10
6
Z49.0
ICD-10 Finland
Preparatory care for dialysis
41.7
6.8
8
*
SPAT1262
SPAT
Handing over of treatment supplies
2.8
6.8
39
162
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.8
6.7
18
34
I10
ICD-10 Finland
Essential (primary) hypertension
2.3
6.6
111
746
A46
ICD-10 Finland
Erysipelas
2.8
6.5
36
146
WZC00
NOMESCO Finland
Treatment plan or consultation
2.3
6.5
74
422
A41.9
ICD-10 Finland
Sepsis, unspecified
5.6
6.5
18
35
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.4
6.5
25
82
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.4
6.5
25
82
E86
ICD-10 Finland
Volume depletion
72.3
6.5
7
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.1
6.4
29
105
L04AA06
ATC
mycophenolic acid; systemic
11.6
6.4
11
10
A07AA02
ATC
nystatin; oral
5.8
6.3
17
32
B03BA03
ATC
hydroxocobalamin; parenteral
4.3
6.3
17
43
2700A
ICD-9 Finland
Disorders of amino-acid transport and metabolism, Disturbances of amino-acid transport[CYSTINURIA]
+∞
6.3
6
*
A16AX03
ATC
sodium phenylbutyrate; oral
+∞
6.3
6
*
N16.3*E72.0
ICD-10 Finland
Renal tubulo-interstitial disorders in cystinosis
+∞
6.3
6
*
N18.0
ICD-10 Finland
End-stage renal disease
27.7
6.3
8
*
SPAT1215
SPAT
Assessment of need for medical rehabilitation
8.1
6.2
13
17
B81
ICPC
Anaemia vit B12/folate deficiency
7.1
6.2
14
21
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
9.1
6.2
12
14
127
Kela drug reimbursment
Transplant complication
13.1
6.2
10
8
A12AA04
ATC
calcium carbonate; oral
13.1
6.2
10
8
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
6.1
52
262
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
7.7
6.0
13
18
R4190
NOMESCO Finland
Nutritional therapy
4.3
6.0
16
40
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
188
4.98
22.46
18.0
5.9
1.13
1.10
mmol/l
0.40
60
171
43
90
5.97
20.67
8.9
3.2
115.33
87.49
ng/l
0.55
38
78
52
155
4.32
16.18
11.5
4.0
1.63
2.23
mmol/l
0.47
43
130
40
106
4.57
14.37
5.8
6.6
0.81
1.75
mmol/l
0.52
29
86
61
232
3.47
13.06
5.9
4.5
0.80
0.81
mmol/l
0.55
53
219
113
651
3.00
11.36
19.7
6.2
1.20
1.21
mmol/l
1.22
106
608
34
97
4.09
10.96
2.1
1.5
—
—
—
0
0
25
63
4.45
9.41
7.0
2.5
0.97
1.53
g/l
2.11
20
56
49
200
3.00
8.97
11.1
5.9
103.20
104.83
mmol/l
1.56
49
200
35
120
3.38
8.55
14.6
8.3
25.55
25.13
mmol/l
0.23
35
120
49
212
2.81
7.99
7.0
2.1
30.28
29.07
s
0.62
49
205
70
362
2.53
7.99
5.6
2.7
347.35
341.76
umol/l
0.15
62
320
98
593
2.44
7.91
3.5
2.0
94.06
98.24
pmol/l
0.34
59
307
52
238
2.67
7.57
2.4
2.0
—
—
—
0
0
75
410
2.43
7.50
8.2
3.6
33.42
8.87
mg/mmol
1.23
51
253
43
182
2.79
7.25
2.4
1.9
—
—
—
0
0
52
247
2.56
6.96
2.7
1.7
1490.17
1264.14
nmol/l
0.56
42
186
110
729
2.32
6.86
23.8
6.4
1.20
1.21
mmol/l
0.50
92
634
98
629
2.23
6.47
5.2
2.4
72.38
75.02
nmol/l
0.44
89
562
69
386
2.28
6.35
3.6
2.0
3.77
2.94
mg/l
1.57
62
345
16
39
4.41
6.23
1.4
1.3
227.00
282.42
ug/g
—
10
20
39
172
2.62
6.01
2.5
2.0
—
—
—
0
0
16
41
4.19
5.85
1.6
2.0
—
—
—
0
0
9
7
13.44
5.64
3.6
2.4
—
—
—
0
0
16
43
3.99
5.50
1.2
1.2
—
—
—
0
0
36
160
2.56
5.44
5.2
3.2
8.44
7.36
umol/l
0.19
27
138
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
31
5.18
5.26
5.3
2.8
0.31
0.28
iu/ml
—
9
20
99
675
2.04
5.20
6.9
2.8
342.64
123.86
ug/l
1.58
92
632
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
7
5
14.48
4.61
1.7
3.2
172.57
121.00
%
—
7
5
15
39
4.10
4.31
1.7
1.7
—
—
—
0
0
64
395
1.97
4.27
2.4
1.6
20.64
19.70
nmol/l
0.20
51
333
24
98
2.67
4.26
2.7
2.7
53.11
72.50
ml/min/173m2
—
9
36
79
528
1.89
4.12
5.7
3.7
79.61
38.30
ng/l
0.73
66
384
33
161
2.29
4.03
10.5
6.5
—
—
—
0
0
13
32
4.30
3.99
1.6
1.1
—
—
—
0
0
20
77
2.80
3.96
2.1
1.6
—
—
—
0
0
120
929
1.89
3.83
7.3
3.3
61.22
46.95
u/l
1.06
112
882
7
8
9.04
3.80
3.0
2.6
108.14
107.38
%
—
7
8
12
29
4.36
3.78
1.1
1.6
—
—
—
0
0
13
34
4.04
3.78
1.7
1.7
—
—
—
0
0
68
443
1.86
3.78
5.7
2.6
64.89
77.44
u/l
0.39
62
408
19
75
2.72
3.60
9.7
2.8
0.57
0.66
%
0.91
19
75
19
75
2.72
3.60
9.7
2.8
0.95
1.36
%
1.38
19
75
6
6
10.29
3.52
1.2
1.0
—
—
—
0
0
11
27
4.27
3.46
1.2
1.3
—
—
—
0
0
11
27
4.27
3.46
1.2
1.3
—
—
—
0
0
29
145
2.19
3.34
15.3
7.2
112.76
121.21
g/l
1.46
29
140
65
433
1.79
3.28
7.4
3.2
0.49
0.40
e6/l
0.17
57
324
22
99
2.39
3.22
15.0
7.4
93.22
93.79
%
0.17
22
99
17
68
2.66
3.15
4.3
9.3
8.71
9.20
kpa
0.61
17
68
55
353
1.81
3.12
1.4
1.4
1.08
1.88
u/ml
0.45
14
79
11
31
3.71
3.05
9.2
3.3
4.80
4.95
kpa
0.35
11
31
54
347
1.80
3.04
5.1
2.2
—
—
—
0
0
9
21
4.45
3.04
1.8
1.5
—
—
—
0
0
9
21
4.45
3.04
1.4
1.2
—
—
—
0
0
10
26
4.01
3.03
1.2
2.0
—
—
—
0
0
18
76
2.52
3.00
17.2
7.6
14.66
15.64
%
0.75
18
71
5
5
10.23
2.99
4.0
1.6
82.32
178.32
ug/l
—
5
5
32
174
2.02
2.97
14.7
6.6
11.19
12.11
kpa
0.47
32
166
32
174
2.02
2.97
14.7
6.6
5.08
5.21
kpa
0.26
32
165
64
439
1.71
2.85
3.8
3.2
3349.98
1412.36
ng/l
0.78
51
374
9
23
4.06
2.81
6.1
4.8
8.00
5.65
pmol/l
—
9
23
32
178
1.97
2.79
2.3
2.2
1.65
1.46
%
0.60
26
155
50
325
1.75
2.68
5.5
1.6
10.13
1.10
mg/l
1.30
38
251
10
30
3.47
2.65
2.0
3.2
15.11
15.91
%
—
10
30
41
257
1.77
2.47
7.0
3.0
3.06
1.57
e6/l
0.49
21
132
11
41
2.79
2.25
1.8
1.5
—
—
—
0
0
19
96
2.10
2.15
15.1
6.5
23.74
24.89
mmol/l
0.46
19
90
60
432
1.58
2.13
6.4
4.4
0.00
0.00
estimate
-0.00
17
145
7
20
3.60
2.07
1.3
1.4
—
—
—
0
0
9
32
2.91
2.03
2.1
1.7
—
—
—
0
0
10
39
2.65
1.97
2.0
1.5
169.20
286.21
u/ml
—
5
24
5
11
4.64
1.95
1.2
1.3
—
—
—
0
0
24
137
1.87
1.95
8.2
3.5
—
—
—
0
0
42
283
1.63
1.94
6.5
2.8
0.90
0.77
e6/l
0.10
23
159
12
52
2.40
1.92
2.6
3.1
—
—
—
0
0
5
12
4.25
1.83
1.0
1.2
—
—
—
0
0
5
12
4.25
1.83
1.2
1.3
—
—
—
0
0
5
12
4.25
1.83
1.2
1.3
—
—
—
0
0
5
12
4.25
1.83
1.0
1.2
—
—
—
0
0
5
12
4.25
1.83
1.2
1.3
—
—
—
0
0
5
12
4.25
1.83
1.2
1.3
—
—
—
0
0
124
1070
1.52
1.78
5.5
4.0
14.73
14.80
pmol/l
0.12
115
982
5
13
3.92
1.72
1.0
1.2
—
—
—
0
0
5
13
3.92
1.72
1.0
1.2
—
—
—
0
0
5
13
3.92
1.72
1.2
1.2
—
—
—
0
0
10
40
2.59
1.69
2.0
1.4
—
—
—
0
0
6
19
3.23
1.67
1.3
1.3
—
—
—
0
0
92
755
1.45
1.66
6.7
4.0
0.00
0.00
estimate
-0.00
19
157
5
14
3.64
1.62
1.0
1.2
—
—
—
0
0
104
879
1.44
1.57
15.2
10.0
3.98
4.05
e9/l
0.08
99
767
28
180
1.66
1.55
5.6
4.5
30.44
33.18
%
0.38
18
121
5
15
3.40
1.53
2.2
1.9
1.00
1.00
index
—
5
15
92
766
1.41
1.48
6.8
4.0
0.00
0.00
estimate
-0.00
20
159
7
28
2.56
1.46
2.0
1.7
—
—
—
0
0
82
673
1.40
1.42
6.0
2.7
—
—
estimate
—
0
0
15
82
1.91
1.40
1.1
1.4
37.83
111.71
u/ml
—
6
39
46
340
1.48
1.40
5.9
4.2
1.02
1.02
kg/l
0.10
34
215
92
772
1.39
1.39
6.9
4.1
0.00
1.95
estimate
0.50
18
154
20
121
1.74
1.37
4.8
2.5
66.02
66.80
g/l
0.16
20
112
5
17
2.99
1.37
1.0
1.3
—
—
—
0
0
6
24
2.55
1.31
1.2
1.2
—
—
—
0
0
5
18
2.83
1.29
1.6
2.1
—
—
—
0
0
8
35
2.34
1.28
1.1
1.1
—
—
—
0
0
8
36
2.28
1.26
1.3
1.5
—
—
—
0
0
8
36
2.28
1.26
1.1
1.1
—
—
—
0
0
6
25
2.45
1.25
1.7
1.9
—
—
—
0
0
154
1434
1.53
1.16
37.5
15.1
27.98
25.04
mg/l
0.48
140
1162
13
76
1.77
1.02
1.3
1.3
—
—
—
0
0
0
32
0.00
0.96
0.0
1.7
—
—
—
0
0
9
152
0.57
0.93
1.6
2.4
—
—
—
0
0
8
45
1.81
0.85
2.3
1.5
—
—
—
0
0
140
1303
1.34
0.85
6.6
4.8
1.98
1.90
mu/l
0.35
128
1187
11
65
1.74
0.84
1.5
1.3
—
—
—
0
0
8
46
1.77
0.83
2.3
1.9
—
—
—
0
0
23
311
0.70
0.82
3.9
3.1
0.75
0.76
ug/l
0.02
17
206
0
24
0.00
0.80
0.0
1.7
—
—
—
0
0
0
24
0.00
0.80
0.0
1.5
—
55.85
—
0
24
34
264
1.36
0.79
5.7
3.6
539.54
698.77
ng/l
0.17
24
189
11
171
0.62
0.76
1.6
2.6
—
—
—
0
0
7
42
1.69
0.69
2.1
1.7
—
—
—
0
0
13
87
1.53
0.65
1.1
1.0
—
—
—
0
0
135
1271
1.25
0.61
6.2
4.0
1.51
1.25
mmol/l
2.29
123
1162
23
291
0.76
0.55
1.8
1.8
—
—
—
0
0
6
38
1.60
0.55
1.2
1.3
—
—
—
0
0
115
1074
1.20
0.52
6.2
4.4
20.73
11.29
mm/h
4.00
100
999
135
1283
1.21
0.48
10.5
5.7
42.87
38.97
mmol/mol
3.01
123
1204
62
552
1.19
0.47
3.0
1.8
1.78
1.34
mmol/l
2.51
53
466
139
1328
1.21
0.45
7.1
4.6
1.35
1.46
mmol/l
2.10
126
1227
36
417
0.83
0.42
4.8
4.7
22.60
21.16
%
0.21
15
210
5
34
1.48
0.40
1.2
1.5
—
—
—
0
0
38
434
0.84
0.38
8.1
3.4
0.00
0.19
estimate
0.50
14
130
139
1338
1.17
0.35
7.1
4.6
4.27
4.60
mmol/l
3.29
127
1246
137
1320
1.16
0.33
33.9
14.2
74.64
81.76
ml/min/173m2
2.16
130
1203
7
53
1.33
0.31
2.0
1.6
—
—
—
0
0
141
1364
1.16
0.30
7.4
5.2
2.39
2.69
mmol/l
3.63
127
1261
16
131
1.24
0.28
4.1
2.2
11.92
14.12
nmol/l
0.60
11
120
84
889
0.90
0.27
4.0
3.3
—
—
—
0
0
5
38
1.32
0.23
1.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
104.28
—
0
11
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
4.2
—
0.58
—
0
12
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
49
520
0.92
0.15
5.2
5.4
2.18
2.78
ug/l
0.30
38
463
25
229
1.11
0.13
1.2
1.4
32.25
13.00
u/ml
—
6
97
14
123
1.15
0.13
1.3
1.5
—
—
—
0
0
12
106
1.14
0.10
1.6
2.1
—
—
—
0
0
5
47
1.07
0.09
1.2
1.7
1.24
8.19
mg/l
—
5
35
61
591
1.05
0.08
6.9
4.0
0.00
0.00
estimate
-0.00
14
139
8
91
0.87
0.07
1.8
2.0
—
—
—
0
0
131
1326
0.96
0.06
7.0
4.8
6.41
5.89
mmol/l
2.35
118
1214
19
200
0.94
0.04
1.3
1.4
—
—
—
0
0
122
1209
1.03
0.03
44.5
18.5
14.27
13.63
%
4.34
122
1197
26
255
1.02
0.00
1.3
1.4
9.45
31.61
iu/ml
—
6
86
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
43.14
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_AMINO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_AMINO | 2.512 [1.93, 3.26] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.091 |
During the follow-up period (1.1.1998 — 31.12.2019), 205 out of 578 females with E4_AMINO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_AMINO | 3.747 [2.76, 5.09] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 230 out of 601 males with E4_AMINO died.
Mortality risk
Mortality risk for people of age
years, who have E4_AMINO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.268% | 0.683% |
| 5 | 1.525% | 4.062% |
| 10 | 3.659% | 10.004% |
| 15 | 6.716% | 18.481% |
| 20 | 11.084% | 29.844% |
Relationships between endpoints
↥Index endpoint: E4_AMINO – Other disorders of amino-acid metabolism
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data